Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparing Empagliflozin With Dapagliflozin in Diabetic Patients With CKD
NCT07866235Completed
- Sponsor
- Lahore General Hospital
- Start
- Oct 2023
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
Randomised trial of empagliflozin in diabetic nephropathy (DN), type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) (2 arms), sponsored by Lahore General Hospital. Primary endpoints: Change in urinary albumin-to-creatinine ratio at 4 months, Change in glycated haemoglobin at 4 months and 2 more. Started Oct 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
diabetic nephropathy (DN)type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07866235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07866235.